Bionano Genomics (NASDAQ:BNGO) Trading Down 4.2%

Bionano Genomics, Inc. (NASDAQ:BNGO)’s stock price traded down 4.2% on Wednesday . The company traded as low as $0.76 and last traded at $0.76. 795,720 shares were traded during trading, a decline of 52% from the average session volume of 1,645,953 shares. The stock had previously closed at $0.79.

Analyst Upgrades and Downgrades

Separately, Scotiabank lowered their price objective on shares of Bionano Genomics from $7.00 to $6.00 and set a “sector outperform” rating for the company in a research report on Thursday, March 7th.

Bionano Genomics Price Performance

The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.17 and a current ratio of 1.40. The business’s 50 day simple moving average is $1.07 and its 200-day simple moving average is $1.38. The stock has a market capitalization of $41.62 million, a price-to-earnings ratio of -0.11 and a beta of 2.33.

Bionano Genomics (NASDAQ:BNGO) last posted its earnings results on Tuesday, March 5th. The company reported ($0.96) earnings per share (EPS) for the quarter. The firm had revenue of $10.72 million for the quarter. Bionano Genomics had a negative net margin of 643.74% and a negative return on equity of 103.68%. Research analysts anticipate that Bionano Genomics, Inc. will post -2.35 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Carret Asset Management LLC acquired a new position in Bionano Genomics during the 4th quarter valued at about $34,000. Headlands Technologies LLC acquired a new stake in shares of Bionano Genomics in the 4th quarter worth approximately $72,000. Cantor Fitzgerald L. P. lifted its stake in shares of Bionano Genomics by 22.2% in the 4th quarter. Cantor Fitzgerald L. P. now owns 55,000 shares of the company’s stock worth $104,000 after acquiring an additional 10,000 shares during the period. Quadrature Capital Ltd acquired a new stake in shares of Bionano Genomics in the 4th quarter worth approximately $209,000. Finally, Dark Forest Capital Management LP lifted its stake in shares of Bionano Genomics by 1,024.2% in the 3rd quarter. Dark Forest Capital Management LP now owns 141,747 shares of the company’s stock worth $429,000 after acquiring an additional 129,138 shares during the period. 11.35% of the stock is owned by institutional investors and hedge funds.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.